Another piece of bad news has come out for St. Jude Medical (NYSE: STJ) regarding an FDA report on defibrillator lead Durata, bringing shares down 12%. In this video, Motley Fool health-care analyst David Williamson talks about how these findings add to a recent string of product difficulties for St. Jude, and how, as an investor, if you see this as the company turning a corner, then it could be a cheap entry point.
More bad news for a company already plagued by product problems.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid
